Dolutegravir: an exciting new kid on the block.
BACKGROUND
Dolutegravir is the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals.


METHODS
Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitro studies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented in international meetings.


CONCLUSIONS
Data from studies and clinical trials indicate that dolutegravir is safe, well tolerated and highly efficacious in the treatment of both antiretroviral-naïve and treatment-experienced patients and appears to have a higher genetic barrier to resistance than first-generation integrase inhibitors.
University of Barcelona, IDIBAPS, Hospital Clinic , Barcelona , Spain JLBLANCO@clinic.ub.es.
Jose Luis
JL
Blanco Arévalo
Gary George
GG
Whitlock
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D024882:Drug Resistance, Viral / Q000235:genetics; D015316:Genetic Therapy; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology; D019427:HIV Integrase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D019428:HIV Integrase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006575:Heterocyclic Compounds, 3-Ring / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009154:Mutation; D010078:Oxazines; D010879:Piperazines; D011487:Protein Conformation; D011728:Pyridones; D000099226:Dolutegravir
D019427:HIV Integrase; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir; C514801:p31 integrase protein, Human immunodeficiency virus 1